Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:MDVN

(MDVN) (MDVN) Stock Price, News & Analysis

(MDVN) logo

About (MDVN) Stock (NASDAQ:MDVN)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$81.44
$81.44
50-Day Range
N/A
52-Week Range
$26.41
$81.48
Volume
N/A
Average Volume
3.55 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc. (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe and other countries across the world for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company, in collaboration with Astellas, is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. It has developed a small molecule inhibitor of the sterol regulatory element-binding protein, or SREBP, pathway which it refers to as MDV4463.

Remove Ads
Receive MDVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (MDVN) and its competitors with MarketBeat's FREE daily newsletter.

MDVN Stock News Headlines

DOGE officially begins retirement transformation
Elon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retirement" process . This fired the starting gun on the biggest economic transformation in American history.
Notable ETF Outflow Detected - HYLB
See More Headlines

MDVN Stock Analysis - Frequently Asked Questions

(MDVN) (NASDAQ:MDVN) posted its quarterly earnings results on Tuesday, August, 9th. The biopharmaceutical company reported $0.29 earnings per share for the quarter, topping analysts' consensus estimates of $0.27 by $0.02. The business's revenue was up 17.4% compared to the same quarter last year.

Based on aggregate information from My MarketBeat watchlists, some other companies that (MDVN) investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX) and (KITE) (KITE).

Company Calendar

Last Earnings
8/09/2016
Today
3/24/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MDVN
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:MDVN) was last updated on 3/25/2025 by MarketBeat.com Staff
From Our Partners